MSCs from de novo AML patients [median 1.50 (range 0.43–3.69)] presented higher ARHGAP21 expression compared to MSCs from HD [0.13 (0.07–1)], p = 0.0035. This evidence concerns the gene ARHGAP21 and acute myeloid leukemia.